4 unknown, 3 completed, 3 terminated, 2 active not recruiting. 12 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Unknown 4, Completed 3, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow FOLFIRI Protocol: new trials by email Literature Review of FOLFIRI Protocol trials Research Report on FOLFIRI Protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Ivonescimab, Bevacizumab, FOLFIRI Protocol - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | UNICANCER | 130 | 2026-08-31 | 2026-05-19 |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NEO212 Oral Capsule, Ipilimumab, Pembrolizumab - Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1 / Phase 2 | Recruiting | Neonc Technologies, Inc. | 134 | 2023-11-01 | 2026-09-24 |
| RP-6306 in Patients With Advanced Cancer RP-6306, Gemcitabine, FOLFIRI Protocol - Advanced Cancer | Phase 2 | Completed | Canadian Cancer Trials Group | 28 | 2023-05-24 | 2026-02-06 |
| SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies SI-B001, Irinotecan, FOLFIRI Protocol - Colorectal Cancer | Phase 2 | Terminated | Sichuan Baili Pharmaceutical Co., Ltd. | 7 | 2021-11-30 | 2024-07-18 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors SM08502, Abiraterone, Prednisone - Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer | Phase 1 | Terminated | Biosplice Therapeutics, Inc. | 30 | 2021-11-03 | 2024-08-09 |
| Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC Panitumumab, Cetuximab, Irinotecan - Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | University of Wisconsin, Madison | 34 | 2020-10-19 | 2026-06-10 |
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI FOLFIRI Protocol, SCO-101 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Scandion Oncology A/S | 35 | 2020-05-14 | 2022-03-02 |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol - Metastatic Colon Cancer, Stage III Colon Cancer | Phase 3 | Active not recruiting | Massachusetts General Hospital | 400 | 2020-04-16 | 2026-09-09 |
| Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. oxaliplatin, FOLFIRI Protocol, Bevacizumab - Liver Metastasis Colon Cancer | Phase 2 | Unknown | Rabin Medical Center | 49 | 2020-01-01 | 2020-10-20 |
| Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma Durvalumab, Tremelimumab, FOLFIRI Protocol - Gastric Adenocarcinoma, Gastric Cancer | Phase 2 | Unknown | Federation Francophone de Cancerologie Digestive | 107 | 2019-07-17 | 2024-07-08 |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer FOLFOX regimen, FOLFIRI Protocol, Avelumab - Metastatic Colorectal Cancer, MSI | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 132 | 2018-04-24 | 2025-06-29 |
| A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy OFF, FOLFIRI Protocol - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | AIO-Studien-gGmbH | 67 | 2018-01-02 | 2022-01-11 |
| Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma FOLFIRI Protocol - Neuroendocrine Carcinoma | Phase 2 | Unknown | Peking University | 45 | 2017-05-02 | 2017-06-01 |
| Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer FOLFIRI Protocol, Aflibercept Injection - Metastatic Colorectal Cancer | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 41 | 2014-10-01 | 2021-06-07 |
Colorectal Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Stomach Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1)
Federation Francophone de Cancerologie Digestive (3) · AIO-Studien-gGmbH (1) · Biosplice Therapeutics, Inc. (1) · Canadian Cancer Trials Group (1) · Massachusetts General Hospital (1) · Neonc Technologies, Inc. (1) · Peking University (1) · Rabin Medical Center (1) · Scandion Oncology A/S (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1) · UNICANCER (1) · University of Wisconsin, Madison (1)
France (4) · United States (4) · China (2) · Germany (2) · Australia (1) · Canada (1) · Denmark (1) · Israel (1) · Spain (1)
Aparna Parikh, MD (1) · Darrin Beaupre, MD, PhD, CMO (1) · Dustin Deming, MD (1) · Eric Chen (1) · Jacob Hagen Vasehus Schou, MD (1) · Josh Neman, PhD (1) · Julien Taieb, Pr (1) · Stephanie Lheureux (1) · Tom Chen, MD, PhD (1) · Weijian Guo (1) · Yvette Drew (1)
PMID 32921581, PMID 37535388, PMID 38573643, PMID 40275077, PMID 40531517
2018 (1), 2025 (1)